Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYMECYCLINE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYMECYCLINE: Safety Overview

Metric LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN LYMECYCLINE
Total FAERS Reports 10,716 174
Deaths Reported 1,461 0
Death Rate 13.6% N/A
Hospitalizations 545 68
Average Patient Age 72.9 yrs 37.4 yrs
% Female Patients 0.7% 60.6%
FDA Approval Date Mar 23, 2022 N/A
Manufacturer Novartis Pharmaceuticals Corporation N/A
Route INTRAVENOUS N/A
Marketing Status Prescription N/A